ArticleMolecular neurobiology2025
Deciphering the Antidepressant Potential of Piper betle L. Essential Oil and Its Inclusion Complex: Network Pharmacology and Experimental Insights.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the antidepressant effects of Piper betle L. leaf essential oil (PBEO) and its inclusion complex (PBECD) in mice whilst exploring potential mechanisms. Gas chromatography-mass spectroscopy (GC-MS) identified PBEO's compounds, and β-cyclodextrins were used to enhance stability and bioavailability by forming PBECD. Characterization was performed using various analytical techniques. ADME pharmacokinetics, network pharmacology, and molecular docking predicted active compounds, antidepressant targets, and signalling pathways. The Chronic Unpredictable Mild Stress (CUMS) model was used to validate findings, with fluoxetine (20 mg/kg) as the standard. Mice received PBEO and PBECD at 50 mg/kg and 100 mg/kg doses. Behavioural tests, including the open field, sucrose preference, Y-maze, and forced swim tests, assessed antidepressant effects. Toxicity was evaluated during dosing. Serum levels of IL-1β and TNF-α were measured using ELISA, whilst biochemical markers such as glutathione (GSH) and malondialdehyde (MDA) were analysed. ADME and network pharmacology identified six active components targeting 244 depression-related proteins, primarily in the MAPK signalling pathway. Molecular docking confirmed strong binding affinities between the ligands and the obtained proteins from network pharmacology. In vivo results showed PBEO and PBECD reduced depressive behaviours, with PBECD demonstrating superior effects. PBECD (100 mg/kg) significantly reduced immobility time by 42.5% in the forced swim test, increased sucrose preference by 36.8%, and improved Y-maze alternation by 31.7% compared to the control group. Serum levels of IL-1β and TNF-α decreased by 48.3% and 41.2% respectively, whilst GSH levels rose by 35.6% and MDA levels dropped by 39.4%, indicating reduced oxidative stress and inflammation. Modulating MAPK signalling, PBECD emerges as a promising candidate for antidepressant activity than PBEO in preclinical findings, as its complexation with cyclodextrin improves the oils' stability, solubility, and bioavailability, resulting in enhanced efficacy.
Indexed as
Identifiers
40524107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.